Asensus Surgical — TransEnterix — Q3 2019 Earnings Presentation
25 slides from Asensus Surgical's earnings presentation, Nov 13, 2019
Slide 1: Q3 Financial and Operating Results Corporate Update
Q3 Financial and Operating Results Corporate Update November 12, 2019
Slide 2: Speakers on Today's Call
SPEAKERS ON TODAY’S CALL Paul LaViolette Anthony Fernando Joe Slattery Chairman of the President and Executive Vice President Board of Directors Chief Executive Officer and Chief Financial Officer 2
Slide 3: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes statements relating to TransEnterix’ refocused plan for the market development, product advances and key opinion leader buy-in, and regulatory and commercial plans for the Senhance Surgical System and a general corporate update. These statements
Slide 4: Paul LaViolette, Chairman of the Board of Directors
PAUL LAVIOLETTE Chairman of The Board of Directors 4
Slide 5: Anthony Fernando, President and Chief Executive Officer
ANTHONY FERNANDO President and Chief Executive Officer 5
Slide 6: Agenda
AGENDA Q3 QUARTERLY INTRODUCTORY BUSINESS OUTLOOK AND FINANCIAL COMMENTS UPDATE EXPECTATIONS REVIEW 6
Slide 7: Q3 Financial Review
Q3 FINANCIAL REVIEW JOE SLATTERY Executive Vice President and Chief Financial Officer 7
Slide 8: Business Update
BUSINESS UPDATE ANTHONY FERNANDO President and Chief Executive Officer 8
Slide 9: Business Update: What We Know
BUSINESS UPDATE 1 WHAT WE KNOW 2 WHAT WE HAVE LEARNED WHAT WE STILL NEED TO DO 3 9
Slide 10: Business Update: What We Know
BUSINESS UPDATE 1 WHAT WE KNOW 2 WHAT WE HAVE LEARNED WHAT WE STILL NEED TO DO 3 10
Slide 11: What We Know: We Are Uniquely Focused on Digital Laparoscopy
WHAT WE KNOW: WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY On the Market In Development Product Strategy Implications Senhance Lap motion Familiarity for Laparoscopic surgeons Fully reusable instruments Low cost per procedure Standard 5mm and 3mm Instruments Advances MIS benefit Haptic fee
Slide 12: What We Know: Laparoscopic Market Is Large with Limited Robotic Penetration
WHAT WE KNOW: LAPAROSCOPIC MARKET IS LARGE WITH LIMITED ROBOTIC PENETRATION TODAY Current Abdominal Laparoscopic Open robotic surgery surgery Surgery 4mm 6mm procedures procedures (EU and US) ~850k Procedures EU and US (EU and US) . Robotics growth continues at 20+% . 6MM laparoscopic procedures per
Slide 13: What We Know: Senhance Demonstrating Strong Clinical Performance Across the Globe
WHAT WE KNOW: SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE ACROSS THE GLOBE GLOBAL CLINICAL CASE VOLUME GROWTH AP GYN Gen +188% US 21% Surg 47% +86% 2019 YTD* +22% EMEA URO CASE MIX 16% Bariatric Active Sites 6 15 24 7% Colorectal 9% Total Cases 394 548 1232 Adoption across multiple specialty
Slide 14: What We Know: Senhance Value Demonstrated in Multiple Customer Settings
WHAT WE KNOW: SENHANCE VALUE DEMONSTRATED IN MULTIPLE CUSTOMER SETTINGS SITE PERFORMANCE CURRENT FOUNDATIONAL SITES First YTD Annual Location # Surgeons Specialties Case Procedures* Pace Foundational Netherlands Nov - 18 161 175+ 10 GS, GYN, CR, URO Kazakhstan 1 Oct - 18 130 150+ 9 GS, GYN, CR, URO
Slide 15: Business Update: What We Have Learned
BUSINESS UPDATE 1 WHAT WE KNOW 2 WHAT WE HAVE LEARNED WHAT WE STILL NEED TO DO 3 15
Slide 16: What We Have Learned: The Challenges
WHAT WE HAVE LEARNED: THE CHALLENGES 1. We focused too heavily on "sales"… 2. Before the system was broadly attractive... …which required significant investment …first gen software did not perform well …had unfilled portfolio gaps …and resulted in a broad geographic - Advanced Energy approach - 3rd
Slide 17: Business Update: What We Still Need to Do
BUSINESS UPDATE 1 WHAT WE KNOW 2 WHAT WE HAVE LEARNED WHAT WE STILL NEED TO DO 3 17
Slide 18: What We Still Need to Do: Market Development
WHAT WE STILL NEED TO DO: MARKET DEVELOPMENT . Expand utilization, surgeon base, and specialties within existing sites . Rapid implementation of new Senhance programs at strategic sites in focus regions . Increase number of speakers and formalize speaker program . Drive share of voice through multip
Slide 19: What We Still Need to Do: Gathering Evidence to Support Key Value Propositions
WHAT WE STILL NEED TO DO: FOCUSED AND DELIBERATE GATHERING OF EVIDENCE TO SUPPORT KEY VALUE PROPOSITIONS Senhance Maintaining O.R. Efficiency – Cost Effective Robotics - demonstrate how learning curve, camera driving cost savings & enabling a cost control, open platform, hybrid approach, effective r
Slide 20: What We Still Need to Do: Portfolio Expansion
WHAT WE STILL NEED TO DO: PORTFOLIO EXPANSION ARTICULATING INSTRUMENTS DIGITAL SURGICAL TECHNOLOGY . 5mm Articulating Instrument portfolio . Passive and bipolar energy capable DEFECT IDENTIFICATION INSTRUMENT TAGGING AND POINT TO POINT AND MESH SIZING PROJECTION 3D MEASUREMENT . Enabling expanded Se
Slide 21: Business Update Summary
BUSINESS UPDATE Uniquely focused on digital laparoscopy WHAT WE KNOW Market expansion opportunity 1 Senhance value proposition proven in key sites Lessons from the past have informed our go WHAT WE HAVE LEARNED 2 forward strategy Broaden market awareness and expand data that WHAT WE STILL NEED TO DO
Slide 22: Outlook and Expectations
OUTLOOK AND EXPECTATIONS =lFransenteru
Slide 23: 2020 – Senhance and Digital Laparoscopy Recognized as Key Components for Robotic Growth
2020 – SENHANCE AND DIGITAL LAPAROSCOPY RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTH TECHNOLOGY THAT HAS THE ABILITY TO “RIGHT SIZE ROBOTICS” MARKET DEVELOPMENT CLINICAL EVIDENCE PORTFOLIO EXPANSION . 20 “foundational sites” performing . Publication of evidence supporting . Scene cognition and Au
Slide 24: renaciriverne
renaciriverne
Slide 25: “=—lroansEnterbe
“=—lroansEnterbe